Everence Capital Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Everence Capital Management’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-28,980	Closed	-$123K	–	777
2020 Q2	$123K	Hold	28,980	–	–	0.01%	630
2020 Q1	$110K	Hold	28,980	–	–	0.02%	580
2019 Q4	$148K	Hold	28,980	–	–	0.02%	644
2019 Q3	$146K	Hold	28,980	–	–	0.02%	612
2019 Q2	$179K	Hold	28,980	–	–	0.03%	591
2019 Q1	$134K	Buy	+28,980	New	+$131K	0.02%	601

Everence Capital Management's PGNX Position: Q3 2020 in Review

Everence Capital Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q3 2020, closing a stake of 28,980 shares — an estimated $123K sold.

Everence Capital Management first reported a position in PGNX in Q1 2019 and held it in 6 quarters. The position peaked at $179K in Q2 2019. 0 funds tracked by Wall St. Rank hold PGNX as of Q3 2020.

Everence Capital Management reported no remaining Progenics Pharmaceuticals Inc position as of Q3 2020 after selling out during the quarter.
Everence Capital Management sold 28,980 Progenics Pharmaceuticals Inc shares in Q3 2020, an estimated $123K.
Everence Capital Management first reported a position in Progenics Pharmaceuticals Inc in Q1 2019 and held it in 6 quarters.
Everence Capital Management's Progenics Pharmaceuticals Inc position peaked at $179K in Q2 2019.
0 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q3 2020.

Based on Everence Capital Management's 13F filing for Q3 2020, filed 20 Oct 2020.